An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice
Finerenone (Kerendia, BAY948862): Retrospective cohort analysis using the investigator or a delegate at the study site collects secondary/historic data of finerenone usage (patient demographic and clinical characteristics, diagnosis-related, treatment-related, and laboratory data) from clinic specific medical records.
Study summary
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients from India (Indian ethnicity) diagnosed with CKD and T2D prior to initiating finerenone (per the standard diagnostic criteria) and initiated on finerenone per approved label.
* Patient was prescribed finerenone for the first time (drug naïve) for the management of CKD and T2D between 1st August 2022 and 30th April 2024.
* Age 18 years or older at the time of finerenone initiation.
Exclusion Criteria:
* eGFR \<25 mL/min/1.73 m\^2
* Serum potassium \>5.0 mmol/L
* Type 1 diabetes is recorded in the patient record
* Contraindications according to the local marketing authorization - Patient data will be excluded if below information is identified in the patient record at any point from index date to the end of observation period:
* \- Pregnancy.
* \- Lactation.
* \- Patient taking concomitant medications that are strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, ritonavir, nelfinavir, cobicistat, clarithromycin, telithromycin and nefazodone).
* \- Addison's disease.
* Patient was a part of an interventional clinical study between 1st August 2022 and 30th Nov 2024.
Primary outcome measure(s)
Descriptive summary of specialty of prescribing physician — Retrospective data analysis from 2022 to 2024
Date of finerenone initiation — Retrospective data analysis from 2022 to 2024
If patient was receiving finerenone at the time of each follow-up visit (Yes/No) — Retrospective data analysis from 2022 to 2024
Date of discontinuation of finerenone — Retrospective data analysis from 2022 to 2024
Reason for discontinuation of finerenone — Retrospective data analysis from 2022 to 2024
Dose of finerenone treatment — Retrospective data analysis from 2022 to 2024
Frequency of finerenone treatment — Retrospective data analysis from 2022 to 2024
The number of patients who initiated finerenone with a 10-mg dose and 20-mg dose — Retrospective data analysis from 2022 to 2024
The proportion of patients who initiated finerenone with a 10-mg dose and have up-titrated to a 20-mg dose — Retrospective data analysis from 2022 to 2024
The proportion of patients who initiated finerenone with a 20-mg dose and have down-titrated to a 10-mg dose — Retrospective data analysis from 2022 to 2024
Actions taken after finerenone introduction — Retrospective data analysis from 2022 to 2024 Actions include continue treatment, addition of second therapy like SGLT2is, potassium binders, discontinue treatment
Actions taken after stop finerenone prescription — Retrospective data analysis from 2022 to 2024 Actions include initiate alternate therapy like Sodium-glucose transport protein-2 inhibitor (SGLT2is), RAASis or potassium binders, other
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.